经皮肺动脉去神经术(PADN)

Search documents
陈绍良入选中国工程院2025年院士增选有效候选人:从原创术式到国际认可,中国心血管学科的突破之路
Jiang Nan Shi Bao· 2025-08-27 07:14
陈绍良院长长期致力于心血管病学的临床、科研与教学工作,在学术界和临床界均具备广泛影响力。他 现任美国心脏病学院(ACC)、美国心脏学会(AHA)、欧洲心脏学会(ESC)委员,中华医学会心 血管病分会临床研究学组组长、中国病理生理学会血管医学专业委员会常委、中国医师协会心血管内科 医师分会副会长等重要学术职务。他先后获得原卫生部"突出贡献中青年专家"、江苏省"333 高层次人 才培养工程"第一层次人才、美国 SCAI 学会"介入治疗大师"等荣誉称号,也是南京医科大学教学名 师、名医,"最受欢迎研究生导师""南京医科大学十佳研究生导师"。 作为中国心血管介入学科的重要推动者,陈绍良在复杂冠脉病变与肺高压治疗方面的原创性探索,已经 走出国门,进入国际指南。他提出的"双导管双支架挤压术(DK CRUSH)"解决了冠脉分叉病变治疗中 的世界性难题,并在2018年被欧洲心脏病学会《心肌血运重建指南》全球推荐。与此同时,他主导研发 的经皮肺动脉去神经术(PADN),在2022年被正式写入《ESC/ERS 肺动脉高压诊断与治疗指南》,成 为首个进入国际权威指南的中国原创肺动脉高压介入治疗方案。 8月20日,中国科学院、中国工 ...
三个月融两轮,帕母医疗完成新一轮千万美金加轮融资
Sou Hu Cai Jing· 2025-05-21 06:19
Core Insights - Pamu Medical has successfully completed a new round of financing amounting to tens of millions of dollars, led by EQT, a European private equity firm, with continued support from Sequoia Capital [1][3] - The funds raised will primarily be used for Pamu Medical's overseas market expansion, including global clinical registration, product indication expansion, and deepening industrialization systems [1][4] Company Development - Pamu Medical's CEO, Lian Jia, emphasized the importance of results-oriented progress and the commitment to advancing product transformation and global layout, ensuring that valuable Chinese original technologies can operate in broader markets [3][7] - Since its establishment in 2013, Pamu Medical has focused on global innovation, creating a closed loop of "R&D - Clinical - Market" [3][4] - The company's core technology, Percutaneous Pulmonary Artery Denervation (PADN), has been included in authoritative guidelines and has received CE-MDR certification from the EU, as well as humanitarian device exemption (HUD) from the FDA and market approval from the National Medical Products Administration (NMPA) in 2023 [3][4] Product and Market Strategy - Pamu Medical is constructing a global development pathway that is "verifiable, sustainable, and integrable into international standards," with successful commercialization of PADN products in China and ongoing efforts to penetrate international markets [4][5] - The recent financing will support Pamu Medical's strategy of "technology internationalization + path standardization," solidifying its position as a platform for Chinese original medical technology in the global healthcare system [4][5] Investor Perspective - EQT's Executive Director, Zoe Zhu, expressed confidence in Pamu Medical's innovative capabilities in the medical device sector, highlighting the potential of the PADN product in addressing unmet needs in the fields of pulmonary hypertension and heart failure [5][6] - Pamu Medical's Chairman, Cynthia Chen, acknowledged the challenges of establishing Chinese original technology as international standards but expressed confidence in the company's commitment to clinical value and innovation for global patients [7]